Circulating microRNAs can predict chemotherapy-induced toxicities in patients being treated for primary breast cancer.

ABSTRACT:

Purpose

Prescribing NAC for breast cancer is a pragmatic treatment strategy for several reasons; however, certain patients suffer chemotherapy-induced toxicities. Unfortunately, identifying patients at risk of toxicity often proves challenging. MiRNAs are small non-coding RNA molecules which modulate genetic expression. The aim of this study was to determine whether circulating miRNAs are sensitive biomarkers that can identify the patients likely to suffer treatment-related toxicities to neoadjuvant chemotherapy (NAC) for primary breast cancer.

Methods

This secondary exploratory from the prospective, multicentre translational research trial (CTRIAL ICORG10/11-NCT01722851) recruited 101 patients treated with NAC for breast cancer, from eight treatment sites across Ireland. A

SUBMITTER: Davey MG 

PROVIDER: S-EPMC10504160 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature